Kiora Pharmaceuticals Inc (KPRX)vsRegeneron Pharmaceuticals Inc (REGN)
KPRX
Kiora Pharmaceuticals Inc
$0.72
-12.28%
HEALTHCARE · Cap: $4.12M
REGN
Regeneron Pharmaceuticals Inc
$920.69
-0.19%
HEALTHCARE · Cap: $98.40B
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 1689520% more annual revenue ($16.90B vs $1.00M). REGN leads profitability with a 28.5% profit margin vs 0.0%. REGN earns a higher WallStSmart Score of 80/100 (B+).
KPRX
Avoid30
out of 100
Grade: F
REGN
Strong Buy80
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for KPRX.
Margin of Safety
+36.9%
Fair Value
$1497.56
Current Price
$920.69
$576.87 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Strong operational efficiency at 30.4%
Revenue surging 36.3% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 29 of every $100 in revenue as profit
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : KPRX
The strongest argument for KPRX centers on Price/Book, Debt/Equity.
Bull Case : REGN
The strongest argument for REGN centers on Operating Margin, Revenue Growth, Debt/Equity. Profitability is solid with margins at 28.5% and operating margin at 30.4%. Revenue growth of 36.3% demonstrates continued momentum.
Bear Case : KPRX
The primary concerns for KPRX are Revenue Growth, EPS Growth, Market Cap.
Bear Case : REGN
The primary concerns for REGN are Piotroski F-Score.
Key Dynamics to Monitor
KPRX profiles as a value stock while REGN is a growth play — different risk/reward profiles.
REGN carries more volatility with a beta of 0.10 — expect wider price swings.
REGN is growing revenue faster at 36.3% — sustainability is the question.
REGN generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
REGN scores higher overall (80/100 vs 30/100), backed by strong 28.5% margins and 36.3% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Kiora Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Kiora Pharmaceuticals Inc. is a clinical-stage biotechnology firm focused on developing innovative therapies for ocular diseases and neurodegenerative disorders. The company boasts a diverse pipeline of drug candidates aimed at addressing significant unmet medical needs, underpinned by its expertise in drug formulation and delivery. With a strong commitment to enhancing patient outcomes and a solid research framework, Kiora's strategic partnerships and clinical advancements underscore its potential within the biopharmaceutical sector, offering an attractive investment prospect for institutional investors looking to capitalize on the next generation of therapeutics.
Visit Website →Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?